Biologic & Biosimilar RA Drugs Forecast Report – Designed for Decision Makers and Product Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Biologic & Biosimilar RA Drugs Market?
The market size of biologic & biosimilar RA drugs has experienced significant growth in the past few years. It is projected to expand from $13.99 billion in 2024 to $14.71 billion in 2025, with a compound annual growth rate (CAGR) of 5.2%. Factors contributing to the growth during the historical period include market adoption rates, results of clinical trials, changes in market share, long-term patient outcomes, and pricing strategies.
What Growth Rate Is Forecasted for the Biologic & Biosimilar RA Drugs Market by 2029?
The market size of biologic and biosimilar ra drugs is anticipated to experience considerable growth in the forthcoming years, expanding to $19.51 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 7.3%. The increase during the forecast period can be credited to the growth of biologic drug production, competitive markets, healthcare regulations, patient choices, and clinical research and development. Key trends projected during this period encompass an increase in competitive biosimilar markets, tailored treatments and precision therapy, improved drug delivery technologies, emphasis on safety and efficiency, and a patient-oriented healthcare approach.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp
Which Key Companies Are Shaping the Future of the Biologic & Biosimilar RA Drugs Market?
Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.
Which Factors Are Driving Demand in the Biologic & Biosimilar RA Drugs Industry?
The burgeoning geriatric population and a spike in rheumatoid arthritis cases are propelling the biologics and biosimilar RA drugs market. The geriatric population comprises individuals aged 60 years and above. Rheumatoid arthritis is an autoimmune disorder which causes the body’s immune system to assault its healthy cells, leading to joint affliction. The probability of developing this disease amplifies with aging as the immune system weakens. Biologics and biosimilar RA drugs are more effective in treating rheumatoid arthritis than traditional drugs. For example, the World Health Organization (WHO), a health sector of the United Nations in Switzerland, reported that there were approximately 1 billion people worldwide over 60 in the year 2020. This figure is anticipated to escalate to 1.4 billion by 2030 and 2.1 billion by 2050. Moreover, the Centers for Disease Control and Prevention, a US government health agency, predict that the number of adults in the US with arthritis could potentially rise to 78.4 million by 2040, with 34.6 million individuals handling arthritis-related mobility restrictions. Consequently, the escalating elderly population combined with a rise in RA incidences is stimulating growth in the biologics and biosimilars RA drugs market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp
How Is the Biologic & Biosimilar RA Drugs Market Segmented by Several Divisions?
The biologic & biosimilar RA drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
What are the Emerging Market Trends Driving the Growth of the Biologic & Biosimilar RA Drugs Industry?
The biologic & biosimilar RA drugs market is seeing a rise in popularity due to cutting-edge innovations. A primary focal point for significant companies in this field is the creation of biosimilar treatments, such as Dual Concentration Biosimilar Options, offering a cost-effective substitution. In July 2023, for example, Organon, an American healthcare firm, together with Samsung Bioepis, a biopharmaceutical company from South Korea, introduced a biosimilar of Humira (adalimumab) to the US market named HADLIMA. This product, which can be accessed in high and low concentrations, facilitates improved affordability and access for patients suffering from autoimmune diseases. The price of the biosimilar is 85% lower than Humira, leading to an increase in patient access. The Arthritis Foundation endorses HADLIMA’s included autoinjector, and the patient support program named HADLIMA For You, which supplies educational resources and co-pay assistance. HADLIMA can be used to treat a variety of conditions, such as rheumatoid arthritis and Crohn’s disease. It comes in citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL) for a consistent patient care.
Access The Full Report Here:
Which Regions Are Driving Growth in the Biologic & Biosimilar RA Drugs Market?
North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9255
This Report Delivers Insight On:
1. How big is the biologic & biosimilar ra drugs market, and how is it changing globally?
2. Who are the major companies in the biologic & biosimilar ra drugs market, and how are they performing?
3. What are the key opportunities and risks in the biologic & biosimilar ra drugs market right now?
4. Which products or customer segments are growing the most in the biologic & biosimilar ra drugs market?
5. What factors are helping or slowing down the growth of the biologic & biosimilar ra drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
